Rebiotix
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Rebiotix sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Rebiotix: 5 sponsored US clinical trials, none currently recruiting.
Rebiotix sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Enterocolitis Clostridium Difficile Recurrent, with 1 trials.
Upper-quartile sponsor footprint
Rebiotix sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)
NCT03931941
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)
NCT03244644
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
NCT02589847
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
NCT02299570
Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea
NCT01925417
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
| Phase 3 | 2 |
How the Rebiotix archive is shaped
5 indexed studies, none listed as recruiting (0% open); 5 completed (100%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: Enterocolitis Clostridium Difficile Recurrent (1 trial), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Rebiotix: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Rebiotix sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Rebiotix page
5 registered trials is a research-attention snapshot, not an endorsement of Rebiotix or any single study.
- None of Rebiotix's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Enterocolitis Clostridium Difficile Recurrent is the condition Rebiotix studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Enterocolitis Clostridium Difficile Recurrent trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rebiotix pipeline card: 5 registered trials from official public datasets.Report a data error.